Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Director | June 01, 2023 | June 05, 2023 |
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | Director | May 29, 2026 | June 02, 2026 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Director | September 05, 2019 | September 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,459 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 86,459 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.
RAPID MICRO BIOSYSTEMS, INC.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 60,687 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 12,787 · Balance 60,687 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. |
| Series A Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2027-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F3: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
| Series B Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2031-05-29 | Direct | 12,787 |
Reported balance
After 2026-05-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-29 · Grant · Acquired 12,787 · Balance 12,787 F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended. F3: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Trust | 10,000 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 F2: Shares held in family trust as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 29, 2026, the Reporting Person purchased, in a registered direct offering, 12,787 shares of the Issuer's Class A Common Stock, as well as an accompanying Series A Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof) and an accompanying Series B Warrant to purchase 12,787 shares of the Issuer's Class A Common Stock (or pre-funded warrants in lieu thereof). The purchase price of each share of Issuer Class A Common Stock and accompanying Series A and Series B Warrant was $1.955. The issuance of such securities was approved by the Issuer's compensation committee of the board of directors in accordance with Rule 16(b)-3 of the Securities Exchange Act of 1934, as amended.
F2: Shares held in family trust as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
F3: The Series A and Series B Warrants cannot be exercised for shares of the Issuer's Class A Common Stock if, as a result of such exercise, the holder, together with its affiliates and any other persons whose beneficial ownership would be aggregated for purposes of Section 13(d) of the Act, would beneficially own more than 4.99% of the total number of shares of the Issuer's Class A Common Stock then outstanding immediately following such exercise.
VivoSim Labs, INC.
Report date September 05, 2019 · Filed September 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.27 · Expires 2029-09-05 | Direct | 52,000 |
Reported balance
After 2019-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-05 · Grant · Acquired 52,000 · Balance 52,000 F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NanoString Technologies Inc
Report date May 06, 2024 · Filed May 08, 2024
Section 16 reporting ended · disclosed 2024-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,384 |
Reported balance
After 2024-05-06 transaction · row 1
1 source rowRow 1 · 2024-05-06 · Exercise / conversion · Acquired 41,133 · Balance 65,384 F1: The shares have not been delivered to the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-05-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-06 · Exercise / conversion · Disposed 41,133 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock. F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares have not been delivered to the reporting person.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of Issuer's common stock.
F3: Pursuant to the terms of the award, as a result of the closing of the sale of substantially all of the assets of the Company to Bruker Corporation, which constituted a "Change of Control" under the terms of the RSU award agreement, the vesting of the RSUs accelerated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2018 Filed Jan 3, 2018 18:19 UTC | NanoString Technologies Inc NSTG · Entity 15988 | GrantCommon Stock · Derivative | 10,168 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001401708-18-000011 · wf-form4_151502153689519.xml · derivative · entry 1 Malloy Kirk · CIK 0001326794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,168 Underlying: Common Stock · 10,168 shares Expires 2027-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2018. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 20:38 UTC | VivoSim Labs, INC. ONVO · Entity 8386 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-17-050410 · doc4.xml · derivative · entry 1 Malloy Kirk · CIK 0001326794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2027-08-24 F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) August 24, 2018 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 18:07 UTC | NanoString Technologies Inc NSTG · Entity 15988 | GrantStock Option (right to buy) · Derivative | 8,611 | $0.00 Strike: $22.30 | $0.00 |
DisclosureSEC source: 0001209191-17-001344 · doc4.xml · derivative · entry 1 Malloy Kirk · CIK 0001326794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,611 Underlying: Common Stock · 8,611 shares Expires 2026-12-31 F1 · derivative.exercise_date: 100% of the shares subject to the Option vest on the one year anniversary of January 1, 2017. The vesting of shares subject to the Option will accelerate in full upon a "change in control" as defined in the 2013 Equity Incentive Plan. Read SEC document |
| September 12, 2016 Filed Sep 13, 2016 17:20 UTC | NanoString Technologies Inc NSTG · Entity 15988 | GrantStock Option (right to buy) · Derivative | 15,935 | $0.00 Strike: $16.36 | $0.00 |
DisclosureSEC source: 0001209191-16-141200 · doc4.xml · derivative · entry 1 Malloy Kirk · CIK 0001326794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,935 Underlying: Common Stock · 15,935 shares Expires 2026-09-11 F1 · derivative.exercise_date: 50% of the shares subject to the Option vest on the one year anniversary of September 12, 2016 (the "Vesting Commencement Date") and thereafter the remaining 50% of the total shares vest in twelve equal monthly installments on each monthly anniversary of the Vesting Commencement Date, subject to continued service as a director through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.